Smith & Nephew (LON:SN) Sets New 1-Year High – Still a Buy?

Smith & Nephew plc (LON:SN)’s share price hit a new 52-week high during trading on Wednesday . The stock traded as high as GBX 1,258.50 and last traded at GBX 1,255, with a volume of 2359560 shares changing hands. The stock had previously closed at GBX 1,256.

Analyst Upgrades and Downgrades

SN has been the subject of several research analyst reports. Royal Bank Of Canada downgraded Smith & Nephew to a “sector perform” rating and decreased their target price for the stock from GBX 1,700 to GBX 1,350 in a research report on Wednesday, December 17th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Smith & Nephew in a report on Friday, November 7th. Panmure Gordon reissued a “hold” rating and issued a GBX 1,200 price objective on shares of Smith & Nephew in a research report on Tuesday, December 9th. Finally, Citigroup upped their target price on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a “buy” rating in a research note on Friday, October 31st. Two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of GBX 1,381.33.

Smith & Nephew Trading Down 0.9%

The firm has a market capitalization of £13.79 billion, a PE ratio of 45.29, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62. The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The company’s 50-day simple moving average is GBX 1,253.76 and its 200 day simple moving average is GBX 1,274.58.

Insiders Place Their Bets

In other Smith & Nephew news, insider Deepak Nath sold 1,240 shares of Smith & Nephew stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of GBX 1,257, for a total value of £15,586.80. 0.19% of the stock is currently owned by company insiders.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.